Adiponectin vs Insulin Lispro
Head-to-head comparison of Adiponectin (Adiponectin (Acrp30, AdipoQ)) and Insulin Lispro (Insulin lispro (B28-Lys, B29-Pro human insulin analog)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Adiponectin | Insulin Lispro |
|---|---|---|
| Category | Diabetes & Metabolic | Diabetes & Metabolic |
| Full Name | Adiponectin (Acrp30, AdipoQ) | Insulin lispro (B28-Lys, B29-Pro human insulin analog) |
| Molecular Weight | ~26.4 kDa (monomer) | 5808.0 Da |
| Half-Life | ~2-4 h | About 1 hour |
| Amino Acids | 244 | 51 |
| Typical Dose | No approved human dose; research use only | 0.05-0.2 U/kg per meal |
| Route | IV|SC | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 86 | 12000 |
| Research Status | Pre-clinical | Approved |
Adiponectin Benefits
- ✓insulin sensitivity
- ✓fatty-acid oxidation
- ✓AMPK activation
Insulin Lispro Benefits
- ✓Rapid postprandial glucose control
- ✓Flexible premeal timing
- ✓Predictable onset of action
- ✓Useful in basal-bolus regimens
Adiponectin Dosing
not established|not established
Insulin Lispro Dosing
Inject SC 0-15 minutes before meals|Adjust dose to carbohydrate intake and premeal glucose|Often paired with a basal insulin
Adiponectin Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Insulin Lispro Side Effects
- ⚠Hypoglycemia
- ⚠Weight gain
- ⚠Injection-site reactions
Research Overview
Adiponectin
Preclinical and translational studies link adiponectin signaling with better glycemic control, lower inflammation, and improved lipid handling. Recombinant adiponectin and receptor-targeting approaches remain research tools rather than approved diabetes therapies.
Insulin Lispro
Clinical studies show faster onset and shorter duration than regular insulin, improving post-meal glucose control. It is a standard comparator in diabetes pharmacology and closed-loop insulin-delivery research.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.